SCHEMBL6666023

SCHEMBL6666023

O=C1Nc2ccc(C(=O)NCc3ccccc3)cc2C(=O)/C1=C\c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
JAK3 P52333 1/20 0.50
PAK4 O96013 3/20 0.49
PIM1 P11309 1/20 0.48
GRK5 P34947 2/20 0.47
GSK3B P49841 4/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
GAA P10253 1/20 0.47
TSHR P16473 1/20 0.47
LRRK2 Q5S007 1/20 0.46
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
CDC25A P30304 1/20 0.45
CDC25B P30305 1/20 0.45
CTDSP1 Q9GZU7 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
RAF1 P04049 1/20 0.45
IMPDH2 P12268 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6835257 1.00 ALDH1A1 (0.51) ALDH1A1JAK3PAK4PIM1GRK5
SCHEMBL6835421 0.90 DRD2 (0.57) ALDH1A1GRK5MEN1KMT2AGAA
SCHEMBL6680638 0.90 DRD2 (0.57) ALDH1A1GRK5MEN1KMT2AGAA
SCHEMBL6837200 0.85 GRK5 (0.51) ALDH1A1JAK3PAK4PIM1GRK5
SCHEMBL6678879 0.85 GRK5 (0.51) ALDH1A1JAK3PAK4PIM1GRK5
SCHEMBL6835415 0.83 GRK5 (0.49) JAK3PAK4GRK5LRRK2MAPT
SCHEMBL6684775 0.83 GRK5 (0.49) JAK3PAK4GRK5LRRK2MAPT
SCHEMBL6678812 0.83 GRK5 (0.49) JAK3GRK5LRRK2MAPT
SCHEMBL6835306 0.83 GRK5 (0.49) JAK3GRK5LRRK2MAPT
SCHEMBL5777676 0.83 RAF1 (0.70) PAK4PIM1MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors HICKS JAMES LESTER (US) 2004-03-04 US disclosed
WO-2004014388-A1 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors MMP13, MMP26, MMP9 ALDH1A1 1202/4885JAK3 385/4885PAK4 3966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.